A mouse model for studying viscerotropic disease caused by yellow fever virus infection

PLoS Pathogens

Volumn 5, Issue 10, 2009, Pages

  Meier, Kathryn C ^a   Gardner, Christina L ^a   Khoretonenko, Mikhail V ^a   Klimstra, William B ^a   Ryman, Kate D ^a  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA1 INTERFERON; BETA1 INTERFERON; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; STAT1 PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR STAT129; UNCLASSIFIED DRUG; ALPHA BETA INTERFERON RECEPTOR; GAMMA INTERFERON RECEPTOR; INTERFERON RECEPTOR; YELLOW FEVER VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATTENUATION; BLOOD SAMPLING; CLINICAL FEATURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DISEASE COURSE; DISEASE PREDISPOSITION; DISEASE SEVERITY; ENCEPHALITIS; HAMSTER; HOST; HOST PATHOGEN INTERACTION; HUMAN; HUMAN CELL; IMMUNIZATION; IN VITRO STUDY; LIVER; LYMPH NODE; MACROPHAGE; MOUSE; NONHUMAN; PATHOGENESIS; PATHOLOGY; PRIMATE; SIGNAL TRANSDUCTION; SPLEEN; SYMPTOM; TROPICAL DISEASE; VIREMIA; VIRUS REPLICATION; VIRUS STRAIN; VISCERA; VISCEROTROPIC YELLOW FEVER INFECTION; WILD TYPE; YELLOW FEVER; YELLOW FEVER FLAVIVIRUS; ANIMAL; BONE MARROW CELL; DISEASE MODEL; GENETIC PREDISPOSITION; GENETICS; IMMUNOLOGY; LIVER CELL; MICROBIOLOGY; MOSQUITO; MOUSE MUTANT; PATHOGENICITY; PATHOPHYSIOLOGY; VIROLOGY;

ANIMALIA; CRICETINAE; MUS; PRIMATES; YELLOW FEVER VIRUS;

ANIMALS; BONE MARROW CELLS; CRICETINAE; CULICIDAE; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; GENETIC PREDISPOSITION TO DISEASE; HEPATOCYTES; MACROPHAGES; MICE; MICE, KNOCKOUT; PRIMATES; RECEPTOR, INTERFERON ALPHA-BETA; RECEPTORS, INTERFERON; SIGNAL TRANSDUCTION; YELLOW FEVER; YELLOW FEVER VACCINE; YELLOW FEVER VIRUS;

EID: 73649112087     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1000614     Document Type: Article

References (55)

1. Barrett AD, Monath TP (2003) Epidemiology and ecology of yellow fever virus. Adv Virus Res 61: 291-315.
2. Tomori O (2002) Yellow fever in Africa: public health impact and prospects for control in the 21st century. Biomedica 22: 178-210.
3. Monath TP (2005) Yellow fever vaccine. Expert Rev Vaccines 4: 553-574.
4. Monath TP (2008) Treatment of yellow fever. Antiviral Res 78: 116-124.
5. Quaresma JA, Barros VL, Pagliari C, Fernandes ER, Guedes F, et al. (2006) Revisiting the liver in human yellow fever: virus-induced apoptosis in hepatocytes associated with TGF-beta, TNF-alpha and NK cells activity. Virology 345: 22-30.
6. Monath TP, Brinker KR, Chandler FW, Kemp GE, Cropp CB (1981) Pathophysiologic correlations in a rhesus monkey model of yellow fever with special observations on the acute necrosis of B cell areas of lymphoid tissues. Am J Trop Med Hyg 30: 431-443.
7. Quaresma JA, Barros VL, Pagliari C, Fernandes ER, Andrade HF Jr, et al. (2007) Hepatocyte lesions and cellular immune response in yellow fever infection. Trans R Soc Trop Med Hyg 101: 161-168.
8. ter Meulen J, Sakho M, Koulemou K, Magassouba N, Bah A, et al. (2004) Activation of the cytokine network and unfavorable outcome in patients with yellow fever. J Infect Dis 190: 1821-1827.
9. Khaiboullina SF, Rizvanov AA, Holbrook MR, St.Jeor S (2005) Yellow fever virus strains Asibi and 17D-204 infect human umbilical cord endothelial cells and induce novel changes in gene expression. Virology 342: 167-176.
10. Monath TP, Barrett AD (2003) Pathogenesis and pathophysiology of yellow fever. Adv Virus Res 60: 343-395.
11. Theiler M, Smith HH (1937) Effect of prolonged cultivation in vivo upon pathogenicity of yellow fever virus. J Exp Med 65: 767-786.
12. Barrett AD, Monath TP, Barban V, Niedrig M, Teuwen DE (2007) 17D yellow fever vaccines: new insights. A report of a workshop held during the World Congress on medicine and health in the tropics, Marseille, France, Monday 12 September 2005. Vaccine 25: 2758-2765.
13. Querec TD, Akondy RS, Lee EK, Cao W, Nakaya HI, et al. (2009) Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat Immunol 10: 116-125.
14. Gaucher D, Therrien R, Kettaf N, Angermann BR, Boucher G, et al. (2008) Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses. J Exp Med 205: 3119-3131.
15. Martins MA, Silva ML, Marciano AP, Peruhype-Magalhaes V, Eloi-Santos SM, et al. (2007) Activation/modulation of adaptive immunity emerges simultaneously after 17DD yellow fever first-time vaccination: is this the key to prevent severe adverse reactions following immunization? Clin Exp Immunol 148: 90-100.
16. Martins MA, Silva ML, Eloi-Santos SM, Ribeiro JG, Peruhype-Magalhaes V, et al. (2008) Innate immunity phenotypic features point toward simultaneous raise of activation and modulation events following 17DD live attenuated yellow fever first-time vaccination. Vaccine 26: 1173-1184.
17. Pulendran B, Miller J, Querec TD, Akondy R, Moseley N, et al. (2008) Case of yellow fever vaccine-associated viscerotropic disease with prolonged viremia, robust adaptive immune responses, and polymorphisms in CCR5 and RANTES genes. J Infect Dis 198: 500-507.
18. Belsher JL, Gay P, Brinton M, DellaValla J, Ridenour R, et al. (2007) Fatal multiorgan failure due to yellow fever vaccine-associated viscerotropic disease. Vaccine 25: 8480-8485.
19. Quaresma JA, Barros VL, Fernandes ER, Pagliari C, Takakura C, et al. (2005) Reconsideration of histopathology and ultrastructural aspects of the human liver in yellow fever. Acta Trop 94: 116-127.
20. Quaresma JA, Barros VL, Fernandes ER, Pagliari C, Guedes F, et al. (2006) Immunohistochemical examination of the role of Fas ligand and lymphocytes in the pathogenesis of human liver yellow fever. Virus Res 116: 91-97.
21. Arroyo JI, Apperson SA, Cropp CB, Marafino BJ Jr, Monath TP, et al. (1988) Effect of human gamma interferon on yellow fever virus infection. Am J Trop Med Hyg 38: 647-650.
22. Barrett AD, Gould EA (1986) Comparison of neurovirulence of different strains of yellow fever virus in mice. J Gen Virol 67: 631-637.
23. Fitzgeorge R, Bradish CJ (1980) The in vivo differentiation of strains of yellow fever virus in mice. J Gen Virol 46: 1-13.
24. Ryman KD, Ledger TN, Weir RC, Schlesinger JJ, Barrett AD (1997) Yellow fever virus envelope protein has two discrete type-specific neutralizing epitopes. J Gen Virol 78: 1353-1356.
25. Deubel V, Schlesinger JJ, Digoutte JP, Girard M (1987) Comparative immunochemical and biological analysis of African and South American yellow fever viruses. Arch Virol 94: 331-338.
26. Ryman KD, Xie H, Ledger TN, Campbell GA, Barrett AD (1997) Antigenic variants of yellow fever virus with an altered neurovirulence phenotype in mice. Virology 230: 376-380.
27. Tesh RB, Guzman H, da Rosa AP, Vasconcelos PF, Dias LB, et al. (2001) Experimental yellow fever virus infection in the Golden Hamster (Mesocricetus auratus). I. Virologic, biochemical, and immunologic studies. J Infect Dis 183: 1431-1436.
28. Xiao SY, Zhang H, Guzman H, Tesh RB (2001) Experimental yellow fever virus infection in the Golden hamster (Mesocricetus auratus). II. Pathology. J Infect Dis 183: 1437-1444.
29. Sbrana E, Xiao SY, Popov VL, Newman PC, Tesh RB (2006) Experimental yellow fever virus infection in the golden hamster (Mesocricetus auratus) III. Clinical laboratory values. Am J Trop Med Hyg 74: 1084-1089.
30. McArthur MA, Suderman MT, Mutebi JP, Xiao SY, Barrett AD (2003) Molecular characterization of a hamster viscerotropic strain of yellow fever virus. J Virol 77: 1462-1468.
31. Munoz-Jordan JL, Sanchez-Burgos GG, Laurent-Rolle M, Garcia-Sastre A (2003) Inhibition of interferon signaling by dengue virus. Proc Natl Acad Sci U S A 100: 14333-14338.
32. Lin RJ, Liao CL, Lin E, Lin YL (2004) Blocking of the alpha interferon-induced Jak-Stat signaling pathway by Japanese encephalitis virus infection. J Virol 78: 9285-9294.
33. Chung KM, Liszewski MK, Nybakken G, Davis AE, Townsend RR, et al. (2006) West Nile virus nonstructural protein NS1 inhibits complement activation by binding the regulatory protein factor H. Proc Natl Acad Sci U S A 103: 19111-19116.
34. Keller BC, Fredericksen BL, Samuel MA, Mock RE, Mason PW, et al. (2006) Resistance to alpha/beta interferon is a determinant of West Nile virus replication fitness and virulence. J Virol 80: 9424-9434.
35. Shresta S, Sharar KL, Prigozhin DM, Beatty PR, Harris E (2006) Murine model for dengue virus-induced lethal disease with increased vascular permeability. J Virol 80: 10208-10217.
36. Clyde K, Kyle JL, Harris E (2006) Recent advances in deciphering viral and host determinants of dengue virus replication and pathogenesis. J Virol 80: 11418-11431.
37. Kyle JL, Beatty PR, Harris E (2007) Dengue virus infects macrophages and dendritic cells in a mouse model of infection. J Infect Dis 195: 1808-1817.
38. Muller U, Steinhoff U, Reis LF, Hemmi S, Pavlovic J, et al. (1994) Functional role of type I and type II interferons in antiviral defense. Science 264: 1918-1921.
39. Meraz MA, White JM, Sheehan KC, Bach EA, Rodig SJ, et al. (1996) Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. Cell 84: 431-442.
40. Gardner CL, Burke CW, Tesfay MZ, Glass PJ, Klimstra WB, et al. (2008) Eastern and Venezuelan equine encephalitis viruses differ in their ability to infect dendritic cells and macrophages: impact of altered cell tropism on pathogenesis. J Virol 82: 10634-10646.
41. Lee E, Lobigs M (2008) E protein domain III determinants of yellow fever virus 17D vaccine strain enhance binding to glycosaminoglycans, impede virus spread, and attenuate virulence. J Virol 82: 6024-6033.
42. Diamond MS, Shrestha B, Mehlhop E, Sitati E, Engle M (2003) Innate and adaptive immune responses determine protection against disseminated infection by West Nile encephalitis virus. Viral Immunol 16: 259-278.
43. Samuel MA, Diamond MS (2005) Alpha/beta interferon protects against lethal West Nile virus infection by restricting cellular tropism and enhancing neuronal survival. J Virol 79: 13350-13361.
44. Lobigs M, Mullbacher A,Wang Y, Pavy M, Lee E (2003) Role of type I and type II interferon responses in recovery from infection with an encephalitic flavivirus. J Gen Virol 84: 567-572.
45. Diamond MS, Harris E (2001) Interferon inhibits dengue virus infection by preventing translation of viral RNA through a PKR-independent mechanism. Virology 289: 297-311.
46. Shresta S, Kyle JL, Snider HM, Basavapatna M, Beatty PR, et al. (2004) Interferon-dependent immunity is essential for resistance to primary dengue virus infection in mice, whereas T- and B-cell-dependent immunity are less critical. J Virol 78: 2701-2710.
47. Chambers TJ, Diamond MS (2003) Pathogenesis of flavivirus encephalitis. Adv Virus Res 60: 273-342.
48. Couderc T, Chretien F, Schilte C, Disson O, Brigitte M, et al. (2008) A mouse model for chikungunya: Young age and inefficient type-I interferon signaling are risk factors for severe disease. PLoS Pathog 4: e29. doi:10.1371/journal.-ppat.0040029.
49. Doblas A, Domingo C, Bae HG, Bohorquez CL, de Ory F, et al. (2006) Yellow fever vaccine-associated viscerotropic disease and death in Spain. J Clin Virol 36: 156-158.
50. Querec T, Bennouna S, Alkan S, Laouar Y, Gorden K, et al. (2006) Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity. J Exp Med 203: 413-424.
51. Barba-Spaeth G, Longman RS, Albert ML, Rice CM (2005) Live attenuated yellow fever 17D infects human DCs and allows for presentation of endogenous and recombinant T cell epitopes. J Exp Med 202: 1179-1184.
52. Liprandi F, Walder R (1983) Replication of virulent and attenuated strains of yellow fever virus in human monocytes and macrophage-like cells (U937). Arch Virol 76: 51-61.
53. Bourne N, Scholle F, Silva MC, Rossi SL, Dewsbury N, et al. (2007) Early production of type I interferon during West Nile virus infection: role for lymphoid tissues in IRF3-independent interferon production. J Virol 81: 9100-9108.
54. Hildebrand F, Hubbard WJ, Choudhry MA, Frink M, Pape HC, et al. (2006) Kupffer cells and their mediators: the culprits in producing distant organ damage after trauma-hemorrhage. Am J Pathol 169: 784-794.
55. Palmer DR, Fernandez S, Bisbing J, Peachman KK, Rao M, et al. (2007) Restricted replication and lysosomal trafficking of yellow fever 17D vaccine virus in human dendritic cells. J Gen Virol 88: 148-156.